Y-mAbs Reports MAA Submission to EMA for Omburtamab to Treat Pediatric Patients with CNS/Leptomeningeal Metastasis from Neuroblastoma
Shots:
- The company has submitted MAA for Omburtamab to EMA for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma
- The company continues to advance the Omburtamab program addressing the unmet medical need globally and work closely with FDA to resubmit the BLA in Q2 or Q3’21
- Y-mAbs get an exclusive license from MSK while MSK has an institutional financial interest related to the compound and Y-mAbs. Omburtamab is mAb targeting B7-H3 and is radiolabeled before intraventricular CNS administration
Ref: GlobeNewswire | Image: Y-mabs
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com